, Volume 89, Issue 3, pp 297-304

The “portrait” of hereditary breast cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Five to ten per cent of all breast carcinomas are of hereditary origin. Many of them have been associated to mutations in the BRCA1 and BRCA2 susceptibility genes. No “BRCA3” gene has been found to account for the non-BRCA1/BRCA2 breast cancer (BRCAx) families, and BRCAx tumors are increasingly believed to originate from multiple distinct genetic events. Phenotype studies have questioned the existence of specific “portraits” among hereditary breast carcinomas (HBC). They have shown that most BRCA1 tumors have a “basal (epithelial)-like” aspect, while BRCA2 and BRCAx HBC are more heterogeneous. HBC have also been submitted to genetic analyses, notably with the objective of resolving the heterogeneity of BRCAx lesions. The present review aims to summarize recent data on BRCA1, BRCA2, and BRCAx HBC, including hypotheses on the origin of BRCA1 tumors and their paradoxical relations to estrogen-sensitivity.

BreastMed Consortium: Yves-Jean Bignon, Nancy Uhrhammer, Unité d’Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France; Nathalie Zammatteo, José Remacle, URBC, Fondation Universitaire Notre-Dame de la Paix, Namur, Belgium; André Mégarbané, Unité de Génétique Médicale, Université Saint-Joseph, Beirut, Lebanon; Nourredine Ben Jafaar, Abdelaziz Sefiani, Institut National d’Oncologie, Rabat, Morocco; Lotfi Chouchane, Sami Remadi, Laboratoire d’Immuno-Oncologie Moléculaire, Monastir, Tunisia; Amel Ben Ammar-El Gaaied, Laboratoire de Génétique Moléculaire, d’Immunologie et de Biotechnologie, Faculté des Sciences de Tunis, Tunis, Tunisia; Denis Larsimont, Jean-Marie Nogaret, Institut Jules Bordet, Bruxelles, Belgium; Catherine Sibille, Christine Galant, Centre de Génétique Médicale, Université Catholique de Louvain, Bruxelles, Belgium; Françoise de Longueville, Eppendorf Array Technologies (EAT), Namur, Belgium Véronique Vidal, Diagnogène, Aurillac, France.